Fotios Loupakis
福提奥斯·卢帕基斯
MD, PhD
Senior Oncologist, Colorectal Cancer Unit结直肠癌科高级肿瘤科医师
👥Biography 个人简介
Fotios Loupakis is a pioneering Italian translational oncologist specializing in molecular characterization of CRC and EGFR-targeted therapy. He led FOLFOXIRI plus bevacizumab studies (TRIBE trials) and is a key figure in ctDNA-guided EGFR rechallenge strategies redefining CRC precision therapy in 2026.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FOLFOXIRI + Bevacizumab
Led TRIBE and TRIBE2 trials establishing FOLFOXIRI plus bevacizumab as an intensive first-line option for fit metastatic CRC patients, significantly improving PFS and OS.
EGFR Rechallenge with ctDNA
Pioneered ctDNA-guided EGFR rechallenge concept in RAS wild-type CRC, demonstrating that resistance is dynamic and rechallenge with cetuximab is feasible after ctDNA clearance.
Representative Works 代表性著作
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab in metastatic colorectal cancer (TRIBE)
New England Journal of Medicine (2014)
Phase III trial establishing triplet chemotherapy plus bevacizumab as superior first-line treatment for metastatic CRC.
ctDNA dynamics predict cetuximab rechallenge outcomes in RAS wild-type metastatic CRC
Nature Medicine (2021)
Landmark study demonstrating ctDNA-guided EGFR rechallenge feasibility and efficacy in metastatic CRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 福提奥斯·卢帕基斯 的研究动态
Follow Fotios Loupakis's research updates
留下邮箱，当我们发布与 Fotios Loupakis（Istituto Oncologico Veneto IRCCS）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment